Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
>
2022
>
Biogen Expected to Cut Costs by $1B as Industry Braves Economic Instability
Biogen Expected to Cut Costs by $1B as Industry Braves Economic Instability
Read also
Scientists reveal new method that could reduce waste from drug manufacturing
The new method could help to prevent severe side effects caused by enantiomer drugs.
FDA Grants Fast Track Designation to CTX-009 Plus Paclitaxel for Pretreated Biliary Tract Cancer
CTX-009 plus paclitaxel has received FDA fast track designation for pretreated metastatic or locally advanced biliary tract cancer.
Pfizer scores FDA nod for hemophilia B gene therapy, will charge $3.5M per dose
Pfizer will offer a warranty program for its first FDA-approved gene therapy.
Long flu season winds down in US
The U.S. flu season appears to be over. It was long, but it wasn't unusually severe.